Timcodar, formerly known as VX-853, is a novel multidrug resistance Inhibitor. Timcodar was under clinical trials to treat cancaners and other diseases. Timcodar potentiated the activity of ethidium bromide (EtBr), a model efflux substrate, against three clinically significant gram- Staphylococcus aureus, Enterococcus faecalis, and Streptococcus pneumoniae. Similar to reserpine, VX-853 directly blocked EtBr efflux in S. aureus. Furthermore, VX-853 was effective in lowering the MICs of several clinically used antibiotics, including fluoroquinolones, suggesting that VX-853 are representatives of a new class of bacterial efflux inhibitors with the potential for use in combination therapy. References: Grossman TH, Shoen CM, Jones SM, Jones PL, Cynamon MH, Locher CP. The Efflux Pump Inhibitor Timcodar (VX-853) Improves the Potency of Anti-Mycobacterial Agents. Antimicrob Agents Chemother. 2014 Dec 22. pii: AAC.04271-14. [Epub ahead of print] PubMed PMID: 25534740.

纯度：≥98%

CAS：179033-51-3